Company Interview / Lumos's $500M deal lighting the way in diagnostics

Lumos Diagnostics (ASX:LDX) has secured a major distribution deal with Hong Kong-based Phase Scientific, which Doug Ward considers transformational for the company. The agreement grants Phase Scientific exclusive rights to distribute Lumos Diagnostics’ innovative Pheonix product, a point-of-care test designed to differentiate between bacterial and viral respiratory infections. Ward points out this is a rare product in its field, using lateral flow technology similar to COVID-19 tests. The deal is estimated to bring close to half a billion Australian dollars in revenue, representing a significant market opportunity, particularly in the United States, where Ward sees a potential market size of up to US$1.5 billion.

Ward highlights multiple benefits of the Pheonix test, particularly in aiding physicians’ decisions on antibiotic prescriptions. He raises concerns about rising antibiotic resistance, noting that unnecessarily prescribing antibiotics for viral infections diminishes their effectiveness. The technology aims to reduce such prescriptions, thereby helping tackle this growing public health challenge and changing the practice of medicine worldwide.

Additionally, Lumos Diagnostics (ASX:LDX) has secured a $5 million loan facility from its largest shareholders, Tenmile and Ryder Capital, providing extra liquidity as the company progresses towards crucial steps with the FDA. Ward remains optimistic about upcoming announcements, specifically the FDA submission and potential waiver, foreseeing impactful milestones for both the company and its share price.